Glucagon-like Peptide 1 Global Market Report 2025

Global Glucagon like Peptide 1 Market Report 2024

Glucagon-like Peptide 1 Global Market Report 2025 – By Product (Trulicity, Ozempic, Victoza, Rybelsus, Other Types), By Route of Administration (Oral, Parenteral, Other Routes), By End-Users (Hospitals, Specialty Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

Name: Glucagon-like Peptide 1 Global Market Report 2025
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Glucagon-like Peptide 1 Global Market Report 2025

Report Price : $4490.00 | Pages : | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Glucagon-like Peptide 1 Global Market Report 2025

Proud Members Of

Glucagon-like Peptide 1 Market Definition

Glucagon-like peptide 1 refers to a type of amino acid hormone of peptide that is produced in the L-cells of the intestinal epithelial endocrine. Glucagon-like peptide 1 is used to treat diseases and conditions such as diabetes and obesity respectively.

The main glucagon-like peptide 1 product types are trulicity, ozempic, victoza, rybelsus, and others. Trulicity refers to a prescription medicine that is injectable and is used to improve blood sugar. The various routes of administration are oral, parenteral, and others used in hospitals, specialty clinics, and others.

Glucagon-like Peptide 1 Market Segmentation

The glucagon-like peptide 1 market covered in this report is segmented –

1) By Product: Trulicity, Ozempic, Victoza, Rybelsus, Other Types

2) By Route of Administration: Oral, Parenteral, Other Routes

3) By End-Users: Hospitals, Specialty Clinics, Other End Users

Subsegments:

1) By Trulicity: Injection (pre-filled pen), Dosage forms (0.75 mg, 1.5 mg, etc.)

2) By Ozempic: Injection (pre-filled pen), Dosage forms (0.5 mg, 1 mg, etc.)

3) By Victoza: Injection (pre-filled pen), Dosage forms (1.2 mg, 1.8 mg, etc.)

4) By Rybelsus: Oral tablet (3 mg, 7 mg, 14 mg)

5) By Other Types: Experimental formulations, Combination products with other medications, Alternative delivery systems

Glucagon-like Peptide 1 Market Size and growth rate 2025 to 2029: Graph

Glucagon-like Peptide 1 Market Size 2025 And Growth Rate

The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from$20.88 billion in 2024 to $22.37 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to rising prevalence of diabetes, focus on improved diabetes management, patient preference for injectable therapies, clinical efficacy and safety profiles, advancements in diabetes research

Glucagon-like Peptide 1 Market Growth Forecast

The glucagon-like peptide 1 market size is expected to see strong growth in the next few years. It will grow to $31.27 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to emergence of oral glp-1 therapies, focus on personalized medicine, integration in diabetes treatment algorithms, patient-centric approaches in healthcare. Major trends in the forecast period include market expansion in emerging economies, regulatory approvals for new formulations, focus on personalized medicine, patient education and awareness programs, competitive landscape dynamics.

Book your 30 minutes free consultation with our research experts

Glucagon-like Peptide 1 Market Driver: Escalating Diabetes Prevalence Drives The Global Glucagon-Like Peptide 1 Market

The rising prevalence of diabetes is expected to propel the global glucagon-like peptide 1 market going forward. Diabetes is a condition in which the blood sugar, or blood glucose, is too high. Glucagon-like peptide 1 is a medication used to treat conditions such as type 2 diabetes that may lead to weight loss and improved blood sugar. For instance, in January 2022, according to the National Library of Medicine, a US-based center of biomedical informatics and computational biology, it was estimated that global diabetes prevalence in 20-79-year-olds in 2021 was 10.5% (536.6 million people), and it is expected to increase to 12.2% (783.2 million) in 2045. Therefore, the rising prevalence of diabetes will drive glucagon-like peptide 1.

Glucagon-like Peptide 1 Market Driver: Growing Health Awareness Fuels Demand For Glucagon-Like Peptide 1 (GLP-1) Market

Increasing emphasis on personalized medicine is expected to propel the growth of the glucagon-like peptide 1 (GLP-1) market going forward. Personalized medicine refers to a type of medication that prevents, detects, or treats disease using knowledge about a person's genes or proteins. Personalized medicine allows for the tailoring of GLP-1 formulations and dosages based on individual patient needs and preferences. For instance, in 2022, according to the Personalized Medicine Coalition, a US-based professional membership organization, in 2022, the US Food and Drug Administration (FDA) approved 12 personalized medicines, which accounted for approximately 34% of all newly approved therapeutic molecular entities. Therefore, the increasing emphasis on personalized medicine is driving the growth of the glucagon-like peptide 1 (GLP-1) market.

Global Glucagon-like Peptide 1 Market Major Players

Major companies operating in the glucagon-like peptide 1 market include Novo Nordisk AS, Sanofi SA, Eli Lilly and Co, AstraZeneca plc, Pfizer Inc, Boehringer Ingelheim International GmbH, F Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Baxter, Hikma Pharmaceuticals plc, Zealand Pharma A/S, Intarcia Therapeutics Inc., GlaxoSmithKline plc, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Benemae Pharmaceutical Corporation, Adocia, Biocon, Hanmi Pharmaceutical Co Ltd, Ligand Pharmaceuticals Incorporated, Advinus Therapeutics Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Union Chimique Belge, Amylin Pharmaceuticals LLC, Academic Pharmaceuticals Inc, ConjuChem Biotechnologies, MannKind Corporation:, Provention Bio Inc, Regeneron Pharmaceuticals

Global Glucagon-like Peptide 1 Market Trend: Novo Nordisk Introduces Wegovy Therapy For Weight Management

Technological innovations are a key trend gaining popularity in the global glucagon-like peptide 1 market. Major companies operating in the glucagon-like peptide 1 market are launching new and innovative technologies to sustain their position in the market. For instance, in March 2024, Novo Nordisk A/S, a Denmark-based pharmaceutical company, launched Wegovy, the first and only once-weekly glucagon-like peptide 1 therapy for weight management. Wegovy completed the STEP Phase 3a clinical trial program and demonstrated a safe and well-tolerated profile across the program. This product is used by people who struggle with obesity to achieve and maintain weight loss.

Global Glucagon-like Peptide 1 Market Trend: Innovation In Glucagon-Like Peptide 1 Market By Novo Nordisk India

Major companies operating in the Glucagon-like Peptide 1 market are focusing on product innovations such as oral semaglutide to sustain their position in the market. Oral semaglutide refers to a medication for diabetes management that comes in pill form and is taken by mouth. For instance, in January 2022, Novo Nordisk India, an India-based healthcare company that involves clinical trials, manufacturing, and the introduction of new drugs, launched oral semaglutide, a groundbreaking peptide-in-a-pill formulation. This innovation transforms diabetes treatment, offering patients an oral alternative to injections. This enhancer serves a dual purpose by safeguarding semaglutide from degradation in the stomach, a common challenge for peptides, and by enhancing its absorption.

Glucagon-like Peptide 1 Market Merger And Acquisition: Novo Holdings’ Strategic Acquisition Of Catalent Inc.

In March 2024, Novo Holdings A/S, a Denmark-based investment company acquired Catalent Inc for $16.5 billion. With this acquisition, Novo Holdings aims to strengthen its footprint in the high-growth GLP-1 market by leveraging Catalent’s established infrastructure in fill-finish manufacturing, ensuring increased capacity to meet the rising demand for diabetes and weight-loss treatments. Catalent Inc is US-based biotechnology company specializes in advanced delivery technologies and development solutions for pharmaceuticals.

Regional Analysis For The Global Glucagon-like Peptide 1 Market

North America was the largest region in the glucagon-like peptide 1 market in 2024. The regions covered in the glucagon-like peptide 1 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the glucagon-like peptide 1 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Glucagon-like Peptide 1 Market?

The glucagon-like peptide 1 market consists of sales of dulaglutide, albiglutide, semaglutide, and tirzepatide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Glucagon-like Peptide 1 Industry?

The glucagon-like peptide 1 market research report is one of a series of new reports from The Business Research Company that provides glucagon-like peptide 1 market statistics, including glucagon-like peptide 1 industry global market size, regional shares, competitors with a glucagon-like peptide 1 market share, detailed glucagon-like peptide 1 market segments, market trends and opportunities, and any further data you may need to thrive in the glucagon-like peptide 1 industry. This glucagon-like peptide 1 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Glucagon-like Peptide 1 Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$22.37 billion
Revenue Forecast In 2034	$31.27 billion
Growth Rate	CAGR of 8.7% from 2024 to 2033
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	1) By Product: Trulicity, Ozempic, Victoza, Rybelsus, Other Types 2) By Route of Administration: Oral, Parenteral, Other Routes 3) By End-Users: Hospitals, Specialty Clinics, Other End Users Subsegments: 1) By Trulicity: Injection (pre-filled pen), Dosage forms (0.75 mg, 1.5 mg, etc.) 2) By Ozempic: Injection (pre-filled pen), Dosage forms (0.5 mg, 1 mg, etc.) 3) By Victoza: Injection (pre-filled pen), Dosage forms (1.2 mg, 1.8 mg, etc.) 4) By Rybelsus: Oral tablet (3 mg, 7 mg, 14 mg) 5) By Other Types: Experimental formulations, Combination products with other medications, Alternative delivery systems
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Novo Nordisk AS, Sanofi SA, Eli Lilly and Co, AstraZeneca plc, Pfizer Inc, Boehringer Ingelheim International GmbH, F Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Baxter, Hikma Pharmaceuticals plc, Zealand Pharma A/S, Intarcia Therapeutics Inc., GlaxoSmithKline plc, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Benemae Pharmaceutical Corporation, Adocia, Biocon, Hanmi Pharmaceutical Co Ltd, Ligand Pharmaceuticals Incorporated, Advinus Therapeutics Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Union Chimique Belge, Amylin Pharmaceuticals LLC, Academic Pharmaceuticals Inc, ConjuChem Biotechnologies, MannKind Corporation:, Provention Bio Inc, Regeneron Pharmaceuticals
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Glucagon-like Peptide 1 Market Characteristics

3. Glucagon-like Peptide 1 Market Trends And Strategies

4. Glucagon-like Peptide 1 Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Glucagon-like Peptide 1 Growth Analysis And Strategic Analysis Framework

5.1. Global Glucagon-like Peptide 1 PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Glucagon-like Peptide 1 Market Growth Rate Analysis

5.4. Global Glucagon-like Peptide 1 Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Glucagon-like Peptide 1 Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Glucagon-like Peptide 1 Total Addressable Market (TAM)

6. Glucagon-like Peptide 1 Market Segmentation

6.1. Global Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Trulicity

Ozempic

Victoza

Rybelsus

Other Types

6.2. Global Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral

Parenteral

Other Routes

6.3. Global Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Specialty Clinics

Other End Users

6.4. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Trulicity, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Injection (pre-filled pen)

Dosage forms (0.75 mg, 1.5 mg, etc.)

6.5. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Ozempic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Injection (pre-filled pen)

Dosage forms (0.5 mg, 1 mg, etc.)

6.6. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Victoza, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Injection (pre-filled pen)

Dosage forms (1.2 mg, 1.8 mg, etc.)

6.7. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Rybelsus, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral tablet (3 mg, 7 mg, 14 mg)

6.8. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Experimental formulations

Combination products with other medications

Alternative delivery systems

7. Glucagon-like Peptide 1 Market Regional And Country Analysis

7.1. Global Glucagon-like Peptide 1 Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Glucagon-like Peptide 1 Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Glucagon-like Peptide 1 Market

8.1. Asia-Pacific Glucagon-like Peptide 1 Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Glucagon-like Peptide 1 Market

9.1. China Glucagon-like Peptide 1 Market Overview

9.2. China Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Glucagon-like Peptide 1 Market

10.1. India Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Glucagon-like Peptide 1 Market

11.1. Japan Glucagon-like Peptide 1 Market Overview

11.2. Japan Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Glucagon-like Peptide 1 Market

12.1. Australia Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Glucagon-like Peptide 1 Market

13.1. Indonesia Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Glucagon-like Peptide 1 Market

14.1. South Korea Glucagon-like Peptide 1 Market Overview

14.2. South Korea Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Glucagon-like Peptide 1 Market

15.1. Western Europe Glucagon-like Peptide 1 Market Overview

15.2. Western Europe Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Glucagon-like Peptide 1 Market

16.1. UK Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Glucagon-like Peptide 1 Market

17.1. Germany Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Glucagon-like Peptide 1 Market

18.1. France Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Glucagon-like Peptide 1 Market

19.1. Italy Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Glucagon-like Peptide 1 Market

20.1. Spain Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Glucagon-like Peptide 1 Market

21.1. Eastern Europe Glucagon-like Peptide 1 Market Overview

21.2. Eastern Europe Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Glucagon-like Peptide 1 Market

22.1. Russia Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Glucagon-like Peptide 1 Market

23.1. North America Glucagon-like Peptide 1 Market Overview

23.2. North America Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Glucagon-like Peptide 1 Market

24.1. USA Glucagon-like Peptide 1 Market Overview

24.2. USA Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Glucagon-like Peptide 1 Market

25.1. Canada Glucagon-like Peptide 1 Market Overview

25.2. Canada Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Glucagon-like Peptide 1 Market

26.1. South America Glucagon-like Peptide 1 Market Overview

26.2. South America Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Glucagon-like Peptide 1 Market

27.1. Brazil Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Glucagon-like Peptide 1 Market

28.1. Middle East Glucagon-like Peptide 1 Market Overview

28.2. Middle East Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Glucagon-like Peptide 1 Market

29.1. Africa Glucagon-like Peptide 1 Market Overview

29.2. Africa Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Glucagon-like Peptide 1 Market Competitive Landscape And Company Profiles

30.1. Glucagon-like Peptide 1 Market Competitive Landscape

30.2. Glucagon-like Peptide 1 Market Company Profiles

30.2.1. Novo Nordisk AS Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Eli Lilly and Co Overview, Products and Services, Strategy and Financial Analysis

30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis

31. Glucagon-like Peptide 1 Market Other Major And Innovative Companies

31.1. Boehringer Ingelheim International GmbH

31.2. F Hoffmann-La Roche Ltd

31.3. Bristol-Myers Squibb Company

31.4. Baxter

31.5. Hikma Pharmaceuticals plc

31.6. Zealand Pharma A/S

31.7. Intarcia Therapeutics Inc.

31.8. GlaxoSmithKline plc

31.9. Jiangsu Hansoh Pharmaceutical Group Co Ltd

31.10. Shanghai Benemae Pharmaceutical Corporation

31.11. Adocia

31.12. Biocon

31.13. Hanmi Pharmaceutical Co Ltd

31.14. Ligand Pharmaceuticals Incorporated

31.15. Advinus Therapeutics Ltd

32. Global Glucagon-like Peptide 1 Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Glucagon-like Peptide 1 Market

34. Recent Developments In The Glucagon-like Peptide 1 Market

35. Glucagon-like Peptide 1 Market High Potential Countries, Segments and Strategies

35.1 Glucagon-like Peptide 1 Market In 2029 - Countries Offering Most New Opportunities

35.2 Glucagon-like Peptide 1 Market In 2029 - Segments Offering Most New Opportunities

35.3 Glucagon-like Peptide 1 Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Trulicity, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Ozempic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Victoza, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Rybelsus, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Glucagon-like Peptide 1 Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Global Glucagon-like Peptide 1 Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: Asia-Pacific, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: China, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: India, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Japan, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Australia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Indonesia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: South Korea, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Western Europe, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: UK, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Germany, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: France, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Italy, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Spain, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Eastern Europe, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Russia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: North America, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: USA, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Canada, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: South America, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Brazil, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Middle East, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Africa, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 79: Novo Nordisk AS Financial Performance

Table 80: Sanofi SA Financial Performance

Table 81: Eli Lilly and Co Financial Performance

Table 82: AstraZeneca plc Financial Performance

Table 83: Pfizer Inc Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Trulicity, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Ozempic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Victoza, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Rybelsus, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Glucagon-like Peptide 1 Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Global Glucagon-like Peptide 1 Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: Asia-Pacific, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: China, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: India, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Japan, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Australia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Indonesia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: South Korea, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Western Europe, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: UK, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Germany, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: France, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Italy, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Spain, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Eastern Europe, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Russia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: North America, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: USA, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Canada, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: South America, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Brazil, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Middle East, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Africa, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 79: Novo Nordisk AS Financial Performance

Figure 80: Sanofi SA Financial Performance

Figure 81: Eli Lilly and Co Financial Performance

Figure 82: AstraZeneca plc Financial Performance

Figure 83: Pfizer Inc Financial Performance

Opportunities And Strategies Analysis For The Carbon Dioxide Market – Includes Carbon Dioxide Market Analysis

Global Plastic Material And Resins Market Opportunities And Strategies – Forecast To 2030 – Includes Plastic Material And Resins Market Growth

Opportunities And Strategies Analysis For The Water-Based Printing Inks Market – Includes Water-Based Printing Inks Market Size

Global Fatty Acids Market Opportunities And Strategies – Forecast To 2030 – Includes Fatty Acids Market Trends

The Business Research Company offers the biocomposites research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the tile adhesives and stone adhesives market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the acrylonitrile market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the thermoplastic polyurethane market research report 2022 with industry size, share, segments and market growth

Biosimilar Growth Hormones Global Market Report 2025 – By Route Of Administration (Intravenous, Subcutaneous, Intramuscular, Oral), By Application (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome, Other Applications), By Distribution Channel (Hospital And Retail Pharmacy, Online Pharmacy/ePharmacy, Specialty Clinics) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Biosimilar Hormones Global Market Report 2025 – By Type (Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types), By Application (Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics, Other Applications), By Distribution Channel (Hospital And Retail Pharmacy, Online Pharmacy/pharmacy, Specialty Clinics) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Parathyroid Hormone Global Market Report 2025 – By Disease Type (Hypocalcemia, Hypoparathyroidism), By Product Type (Recombinant Parathyroid Hormone, Parathyroid Hormone Analogues), By End-User (Hospitals, Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Hormone Therapy Global Market Report 2025 – By Therapy (Estrogen Hormone Replacement, Growth Hormone Replacement, Thyroid Hormone Replacement, Testosterone Replacement), By Route of Administration (Oral, Parenteral, Other Routes of Administration), By Indication (Menopause, Hypothyroidism, Growth Hormone Deficiency, Other Indications), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies And Stores, Online Pharmacies) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Health Care Social Media Global Market Report 2025 – By Component (Hardware, Software, Services), By Product (YouTube, Twitter, Instagram, Facebook, Tumblr, Snapchat), By End Users (Hospitals, Medical Professionals, Research Institutes, Biotechnology Companies, Patients, Others End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Healthcare Adhesive Tapes Global Market Report 2025 – By Resin Type (Acrylic, Rubber, Silicone, Other Resin Types), By Backing Material Type (Paper, Fabric, Plastic, Other Backing Material Types), By Application (Surgery, Wound Dressing, Splints, Secure IV Line, Ostomy Seal, Hygiene, Bandages, Transdermal Patches, and Blister Protection, Diagnostic, Monitoring and Medical Devices, and Optical Care, Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Healthcare Services Global Market Report 2025 – By Type (Medical And Diagnostic Laboratory Services, Dental Services, Home Health Care And Residential Nursing Care Services, Residential Substance Abuse And Mental Health Facilities, Hospitals And Outpatient Care Centers, Physicians And Other Health Practitioners, All Other Ambulatory Health Care Services, Ambulance Services), By End User Gender (Male, Female), By Type of Expenditure (Public, Private) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Textured Pea Protein Global Market Report 2025 – By Product Type (Yellow Peas, Green Peas), By Nature (Organic, Conventional), By Processing Type (Dry Processing, Wet Processing), By End Use (Food Processing, Animal Feed, Nutraceuticals, Sports Nutrition, Infant Nutrition, Cosmetic And Personal Care, Other End-users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the Glucagon-like Peptide 1 market?

How will the Glucagon-like Peptide 1 market drivers and restraints affect the market dynamics? What forces will shape the Glucagon-like Peptide 1 industry going forward?

The Glucagon-like Peptide 1 market major growth driver - Escalating Diabetes Prevalence Drives The Global Glucagon-Like Peptide 1 Market. For further insights on the Glucagon-like Peptide 1 market, request a sample here

What is the forecast market size or the forecast market value of the Glucagon-like Peptide 1 market?

The Glucagon-like Peptide 1 market size has grown strongly in recent years. The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from$20.88 billion in 2024 to $22.37 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to rising prevalence of diabetes, focus on improved diabetes management, patient preference for injectable therapies, clinical efficacy and safety profiles, advancements in diabetes research The glucagon-like peptide 1 market size is expected to see strong growth in the next few years. It will grow to $31.27 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to emergence of oral glp-1 therapies, focus on personalized medicine, integration in diabetes treatment algorithms, patient-centric approaches in healthcare. Major trends in the forecast period include market expansion in emerging economies, regulatory approvals for new formulations, focus on personalized medicine, patient education and awareness programs, competitive landscape dynamics. For further insights on the Glucagon-like Peptide 1 market, request a sample here

How is the Glucagon-like Peptide 1 market segmented?

The glucagon-like peptide 1 market covered in this report is segmented –
1) By Product: Trulicity, Ozempic, Victoza, Rybelsus, Other Types
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By End-Users: Hospitals, Specialty Clinics, Other End Users Subsegments:
1) By Trulicity: Injection (pre-filled pen), Dosage forms (0.75 mg, 1.5 mg, etc.)
2) By Ozempic: Injection (pre-filled pen), Dosage forms (0.5 mg, 1 mg, etc.)
3) By Victoza: Injection (pre-filled pen), Dosage forms (1.2 mg, 1.8 mg, etc.)
4) By Rybelsus: Oral tablet (3 mg, 7 mg, 14 mg)
5) By Other Types: Experimental formulations, Combination products with other medications, Alternative delivery systems For further insights on the Glucagon-like Peptide 1 market, request a sample here

Which region has the largest share of the Glucagon-like Peptide 1 market? What are the other regions covered in the report?

North America was the largest region in the glucagon-like peptide 1 market in 2024. The regions covered in the glucagon-like peptide 1 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the Glucagon-like Peptide 1 market, request a sample here.

Who are the major players in the Glucagon-like Peptide 1 market?

What are the key trends in the Glucagon-like Peptide 1 market?

Major trends in the Glucagon-like Peptide 1 market include Novo Nordisk Introduces Wegovy Therapy For Weight Management. For further insights on the Glucagon-like Peptide 1 market, request a sample here.

What are the major opportunities in the Glucagon-like Peptide 1 market? What are the strategies for the Glucagon-like Peptide 1 market?

For detailed insights on the major opportunities and strategies in the Glucagon-like Peptide 1 market, request a sample here.

How does the Glucagon-like Peptide 1 market relate to the overall economy and other similar markets?

For detailed insights on Glucagon-like Peptide 1's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Glucagon-like Peptide 1 industry?

For detailed insights on the mergers and acquisitions in the Glucagon-like Peptide 1 industry, request a sample here.

What are the key dynamics influencing the Glucagon-like Peptide 1 market growth? SWOT analysis of the Glucagon-like Peptide 1 market.

For detailed insights on the key dynamics influencing the Glucagon-like Peptide 1 market growth and SWOT analysis of the Glucagon-like Peptide 1 industry, request a sample here.